Drug
Atezolizumab and Bevacizumab
Atezolizumab and Bevacizumab is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Terminated(1)
Other(1)
Detailed Status
Not yet recruiting1
Suspended1
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
not_yet_recruiting125%
suspended125%
terminated125%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
suspendedphase_2
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
NCT05620771
terminatedphase_2
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
NCT05537402
not_yet_recruitingphase_2
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT07018947
recruitingphase_2
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234
Clinical Trials (4)
Showing 4 of 4 trials
NCT05620771Phase 2
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
NCT05537402Phase 2
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
NCT07018947Phase 2
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT02925234Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4